JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization

  • 0Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Journal of Clinical Laboratory Analysis +

|

September 5, 2025

|

September 5, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

A new PI score model, using neutrophil-lymphocyte ratio, GGT, AFP, and TNM stage, accurately predicts overall survival in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). This novel score outperforms existing TNM and BCLC systems for risk stratification.

Area Of Science

  • Hepatology
  • Oncology
  • Medical Statistics

Background

  • Hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) exhibit varied clinical outcomes.
  • Accurate prognosis prediction and risk stratification are essential for personalized HCC treatment strategies.

Purpose Of The Study

  • To develop and validate a novel prognostic model for overall survival (OS) in HCC patients undergoing TACE.
  • The model incorporates key clinical and laboratory factors for improved individual prognosis estimation.

Main Methods

  • Cox regression analyses were employed on data from 180 HCC patients treated with TACE to identify risk factors and construct the prognostic model.
  • Model performance was assessed by comparing its predictive accuracy against the Tumor-Node-Metastasis (TNM) and Barcelona-Clinic Liver-Cancer (BCLC) staging systems.

Main Results

  • A new prognostic index (PI) score was developed, integrating neutrophil-lymphocyte ratio (NLR), γ-glutamyl transpeptidase (GGT), alpha-fetoprotein (AFP), and TNM stage.
  • The PI score demonstrated superior predictive ability for overall survival compared to TNM and BCLC staging systems, with a higher area under the ROC curve (0.746 vs. 0.699 and 0.692, respectively).
  • Patients stratified by PI score into four distinct stages showed statistically significant differences in OS rates (p < 0.001).

Conclusions

  • The PI score offers excellent predictive value for overall survival in HCC patients undergoing TACE.
  • This novel prognostic model surpasses the predictive capabilities of the TNM and BCLC staging systems for this patient cohort.
  • The PI score facilitates more accurate risk stratification, aiding in individualized treatment decisions for HCC patients receiving TACE.

Keywords: